SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5- tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: Biochemical and behavioral profile

Journal of Pharmacology and Experimental Therapeutics

Volumn 310, Issue 3, 2004, Pages 1171-1182

  Aubin, N ^a   Barneoud, Pascal ^a   Carter, C ^a   Caille, D ^a   Sontag, N ^a   Marc, C ^a   Lolivier, J ^a   Gardes, A ^a   Perron, C ^a   Le Kim, A ^a   Charieras, T ^a   Pandini, M ^a   Burnier, P ^a   Puech, F ^a   Jegham, S ^a   George, P ^a   Scatton, B ^a   Curet, O ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYLPHENOXATHIIN 10,10 DIOXIDE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 METHOXYMETHYL 7 (4,4,4 TRIFLUOROBUTOXY) 3,3A,4,5 TETRAHYDRO 1,3 OXAZOLO[3,4 A]QUINOLIN 1 ONE; 3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; BEFLOXATONE; BROFAROMINE; CIMOXATONE; DOPAMINE; HARMALINE; HOMOVANILLIC ACID; LAZABEMIDE; LEVODOPA; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; NORADRENALIN; OXAZOLOQUINOLINONE; OXIDOPAMINE; QUINOLINE DERIVATIVE; SELEGILINE; SEROTONIN; SL 251131; TOLOXATONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN; CHEMICAL ANALYSIS; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG INDICATION; DRUG STRUCTURE; DUODENUM; ENZYME ACTIVITY; EX VIVO STUDY; HYPERACTIVITY; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER; LOCOMOTION; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STRIATE CORTEX; TREMOR;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BENZOPHENONES; BRAIN; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG INTERACTIONS; LEVODOPA; MAZE LEARNING; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; MPTP POISONING; NERVOUS SYSTEM DISEASES; NITROPHENOLS; OXAZOLES; OXIDOPAMINE; PREFRONTAL CORTEX; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; STEREOTYPED BEHAVIOR; TREMOR; TYRAMINE;

EID: 4243189283     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.064782     Document Type: Article

References (38)

1. Agid Y, Javoy-Agid F, and Ruberg M (1995) Biochemistry of neurotransmitters in Parkinson's disease, in Blue Books of Practical Neurology, Movement Disorders 1 and 2 (Marsden CD and Fahn S eds) pp 166-230, Butterworth Heinemann, London, UK.
2. Aubin N, Curet O, Deffois A, and Carter C (1998) Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 71:1635-1642.
3. Barneoud P, Descombris E, Aubin N, and Abrous DN (2000), Evaluation of simple and complex sensorimotor behaviours in rats with a partial lesion of the dopaminergic nigrostriatal system. Eur J Neurosci 12:322-336.
4. Bieck PR and Antonin KH (1989) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm Suppl 28:21-31.
5. Birkmayer W, Knoll J, Riederer P, and Youdim MBH (1983) (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Mod Probl Pharmacopsychiatry 19:170-176.
6. Boudier C and Bieth JG (1989) Mucus proteinase inhibitor: a fast-acting inhibitor of leucocyte elastase. Biochim Biophys Acta 995:36-41.
7. Braestrup C, Andersen H, and Randrup A (1975) The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behavior in rats without inhibition of catecholamine metabolite formation. Eur J Pharmacol 34:181-187.
8. Butcher SP, Fairbrother IS, Kelly JS, and Arbuthnott GW (1990) Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J Neurochem 55:981-988.
9. Caille D, Bergis O, Fankhauser C, Gardes A, Adam R, Charieras T, Grosset A, Rovei V, and Jarreau FX (1996) Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. J Pharmacol Exp Ther 277:265-277.
10. Chase TN, Engber TM, and Mouradian MM (1993) Sriatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease. Adv Neurol 60:181-185.
11. Cotzias GC, Papavasiliou PS, and Gellene R (1969) Modification of Parkinsonism: chronic treatment with L-dopa. N Engl J Med 280:337-345.
12. Curet O, Damoiseau G, Aubin N, Sontag N, Rovei V, and Jarreau FX (1996) Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. J Pharmacol Exp Ther 277:253-264.
13. Curet O, Damoiseau-Ovens G, Sauvage C, Sontag N, Avenet P, Depoortere H, Caille D, Bergis O, and Scatton B (1998) Preclinical profile of befloxatone, a new reversible MAO-A inhibitor. J Affect Disord 51:287-303.
14. Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, and Haefely WE (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248:400-414.
15. Fahn S (1996) Controversies in the therapy of Parkinson's disease. Adv Neurol 69:477-486.
16. Fahn S and Chouinard S (1998) Experience with tranylcypromine in early Parkinson's disease. J Neural Transm Suppl 52:49-61.
17. Heeringa MJ, D'Agostini F, DeBoer P, Da Prada M, and Damsma G (1997) Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior. J Neural Transm 104:593-603.
18. Heikkila RE, Hess A, and Duvoisin RC (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science (Wash DC) 224:1451-1453.
19. Hughes AJ (1997) Drug treatment of Parkinson's disease in the 1990s. Achievements and future possibilities. Drugs 53:195-205.
20. Jacobs BL (1976) An animal behavior model for studying central serotonergic synapses. Life Sci 19:777-785.
21. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285-1297.
22. Kan JP, Steinberg R, Mouget-Goniot C, Worms P, and Biziere K (1987) SR95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition. J Pharmacol Exp Ther 240:251-258.
23. Knoll J and Magyar K (1972) Some puzzling pharmacological effects of monoamines oxidase inhibitors. Adv Biochem Psychopharmacol 5:393-408.
24. Koller WC and Pahwa R (1994) Treating motor fluctuations with controlled-release levodopa preparations. Neurology 44(7 Suppl 6):S23-S28.
25. Kurth MC, Adler CH, Hilaire MS, Singer C, Waters C, LeWitt P, Chernik DA, Dorflinger EE, and Yoo K (1997) Tolcapone improves motor function and reduces levodopa requirements in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 48:81-87.
26. Lang AE and Lozano AM (1998a) Parkinson's disease. First of two parts. N Engl J Med 339:1044-1053.
27. Lang AE and Lozano AM (1998b) Parkinson's disease. Second of two parts. N Engl J Med 339:1130-1143.
28. Lessin AW (1959) The pharmacological evaluation of monoamine oxidase inhibitors. Biochem Pharmacol 2:290-298.
29. Marks MJ, Romm E, Bealer SM, and Collins AC (1985) A test battery for measuring nicotine effects in mice. Pharmacol Biochem Behav 23:325-330.
30. Metman LV, Van den Munckhof P, Klaassen AA, Blanchet P, Mouradian MM, and Chase TN (1997) Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease. Neurology 49:711-713.
31. Morrison JF (1969) Kinetics of the reversible inhibition of enzyme-catalyzed reactions by tight-binding inhibitors. Biochim Biophys Acta 185:269-286.
32. Ortmann R, Shaub M, Felner A, Lauber J, Christen P, and Waldmeier PC (1984) Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors. Psychopharmacology 84:22-27.
33. Ortmann R, Waldmeier PC, Radeke E, Felner A, and Delini-Stula A (1980) The effects of 5-HT uptake and MAO-inhibitors on L-5-HTP-induced excitation in rat. Naunyn-Schmiedeberg's Arch Pharmacol 311:185-192.
34. Parkinson Study Group (1996a) Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 39:37-45.
35. Parkinson Study Group (1996b) Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol 40:99-109.
36. Sieradzan K, Channon S, Ramponi C, Stern GM, Lees AJ, and Youdim MBH (1995) The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease. J Clin Psychopharmacol 15(4 Suppl 2):51S-59S.
37. Strolin-Benedetti M and Dostert P (1985) Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase. Trends Pharmacol Sci 6:246-251.
38. Sundstrom E, Stromberg I, Tsutsumi T, Olson L, and Jonsson G (1987) Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on the central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res 405:26-38.